446 related articles for article (PubMed ID: 29390987)
1. CYP2D6 activity and the risk of recurrence of Plasmodium vivax malaria in the Brazilian Amazon: a prospective cohort study.
Brasil LW; Rodrigues-Soares F; Santoro AB; Almeida ACG; Kühn A; Ramasawmy R; Lacerda MVG; Monteiro WM; Suarez-Kurtz G
Malar J; 2018 Feb; 17(1):57. PubMed ID: 29390987
[TBL] [Abstract][Full Text] [Related]
2. Novel Insights into Plasmodium vivax Therapeutic Failure: CYP2D6 Activity and Time of Exposure to Malaria Modulate the Risk of Recurrence.
Silvino ACR; Kano FS; Costa MA; Fontes CJF; Soares IS; de Brito CFA; Carvalho LH; Sousa TN
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32122891
[No Abstract] [Full Text] [Related]
3. Evaluation of Plasmodium vivax malaria recurrence in Brazil.
Daher A; Silva JCAL; Stevens A; Marchesini P; Fontes CJ; Ter Kuile FO; Lalloo DG
Malar J; 2019 Jan; 18(1):18. PubMed ID: 30670020
[TBL] [Abstract][Full Text] [Related]
4. Association of Impaired Cytochrome P450 2D6 Activity Genotype and Phenotype With Therapeutic Efficacy of Primaquine Treatment for Latent Plasmodium vivax Malaria.
Baird JK; Louisa M; Noviyanti R; Ekawati L; Elyazar I; Subekti D; Chand K; Gayatri A; Instiaty ; Soebianto S; Crenna-Darusallam C; Djoko D; Hasto BD; Meriyenes D; Wesche D; Nelwan EJ; Sutanto I; Sudoyo H; Setiabudy R
JAMA Netw Open; 2018 Aug; 1(4):e181449. PubMed ID: 30646129
[TBL] [Abstract][Full Text] [Related]
5. Association between CYP2D6 phenotype and recurrence of Plasmodium vivax infection in south Korean patients.
Choi S; Choi H; Park SY; Kwak YG; Song JE; Shin SY; Baek JH; Shin HI; Cho SH; Lee SE; Kwon JR; Park S; Kim M; Oh HS; Kim YC; Kim MJ; Yeom JS
Malar J; 2022 Oct; 21(1):289. PubMed ID: 36217154
[TBL] [Abstract][Full Text] [Related]
6. The association of CYP2D6 gene polymorphisms in the full-length coding region with higher recurrence rate of vivax malaria in Yunnan Province, China.
Huang H; Dong Y; Xu Y; Deng Y; Zhang C; Liu S; Chen M; Liu Y
Malar J; 2021 Mar; 20(1):160. PubMed ID: 33743705
[TBL] [Abstract][Full Text] [Related]
7. Multiple relapses of Plasmodium vivax malaria acquired from West Africa and association with poor metabolizer CYP2D6 variant: a case report.
He X; Pan M; Zeng W; Zou C; Pi L; Qin Y; Zhao L; Qin P; Lu Y; Baird JK; Huang Y; Cui L; Yang Z
BMC Infect Dis; 2019 Aug; 19(1):704. PubMed ID: 31399061
[TBL] [Abstract][Full Text] [Related]
8. Several Plasmodium vivax relapses after correct primaquine treatment in a patient with impaired cytochrome P450 2D6 function.
Martin Ramírez A; Lombardia González C; Soler Maniega T; Gutierrez Liarte Á; Domingo García D; Lanza Suárez M; Bernal Fernández MJ; Rubio JM
Malar J; 2020 Jul; 19(1):259. PubMed ID: 32680522
[TBL] [Abstract][Full Text] [Related]
9. Operational effectiveness of tafenoquine and primaquine for the prevention of Plasmodium vivax recurrence in Brazil: a retrospective observational study.
Brito M; Rufatto R; Brito-Sousa JD; Murta F; Sampaio V; Balieiro P; Baía-Silva D; Castro V; Alves B; Alencar A; Duparc S; Grewal Daumerie P; Borghini-Fuhrer I; Jambert E; Peterka C; Edilson Lima F; Carvalho Maia L; Lucena Cruz C; Maciele B; Vasconcelos M; Machado M; Augusto Figueira E; Alcirley Balieiro A; Batista Pereira D; Lacerda M
Lancet Infect Dis; 2024 Jun; 24(6):629-638. PubMed ID: 38452779
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics/pharmacodynamics of chloroquine and artemisinin-based combination therapy with primaquine.
Daher A; Aljayyoussi G; Pereira D; Lacerda MVG; Alexandre MAA; Nascimento CT; Alves JC; da Fonseca LB; da Silva DMD; Pinto DP; Rodrigues DF; Silvino ACR; de Sousa TN; de Brito CFA; Ter Kuile FO; Lalloo DG
Malar J; 2019 Sep; 18(1):325. PubMed ID: 31547827
[TBL] [Abstract][Full Text] [Related]
11. Impact of CYP2D6 Genetic Variation on Radical Cure of Plasmodium vivax Malaria.
Suarez-Kurtz G
Clin Pharmacol Ther; 2021 Sep; 110(3):595-598. PubMed ID: 34042179
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Chloroquine and Primaquine for the Treatment of Uncomplicated Plasmodium vivax Malaria in Cruzeiro do Sul, Brazil.
Negreiros S; Farias S; Viana GM; Okoth SA; Chenet SM; de Souza TM; Marchesini P; Udhayakumar V; Povoa MM; Santelli AC; de Oliveira AM
Am J Trop Med Hyg; 2016 Nov; 95(5):1061-1068. PubMed ID: 27549633
[TBL] [Abstract][Full Text] [Related]
13. The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis.
Commons RJ; Simpson JA; Thriemer K; Humphreys GS; Abreha T; Alemu SG; Añez A; Anstey NM; Awab GR; Baird JK; Barber BE; Borghini-Fuhrer I; Chu CS; D'Alessandro U; Dahal P; Daher A; de Vries PJ; Erhart A; Gomes MSM; Gonzalez-Ceron L; Grigg MJ; Heidari A; Hwang J; Kager PA; Ketema T; Khan WA; Lacerda MVG; Leslie T; Ley B; Lidia K; Monteiro WM; Nosten F; Pereira DB; Phan GT; Phyo AP; Rowland M; Saravu K; Sibley CH; Siqueira AM; Stepniewska K; Sutanto I; Taylor WRJ; Thwaites G; Tran BQ; Tran HT; Valecha N; Vieira JLF; Wangchuk S; William T; Woodrow CJ; Zuluaga-Idarraga L; Guerin PJ; White NJ; Price RN
Lancet Infect Dis; 2018 Sep; 18(9):1025-1034. PubMed ID: 30033231
[TBL] [Abstract][Full Text] [Related]
14. Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms.
Baird JK; Battle KE; Howes RE
Malar J; 2018 Jan; 17(1):42. PubMed ID: 29357870
[TBL] [Abstract][Full Text] [Related]
15. Cytochrome P450 2D6 profiles and their relationship with outcomes of primaquine anti-relapse therapy in Australian Defence Force personnel deployed to Papua New Guinea and East Timor.
Chen N; Dowd S; Gatton ML; Auliff A; Edstein MD; Cheng Q
Malar J; 2019 Apr; 18(1):140. PubMed ID: 30999967
[TBL] [Abstract][Full Text] [Related]
16. Monitoring the Efficacy of Chloroquine-Primaquine Therapy for Uncomplicated Plasmodium vivax Malaria in the Main Transmission Hot Spot of Brazil.
Ladeia-Andrade S; Menezes MJ; de Sousa TN; Silvino ACR; de Carvalho JF; Salla LC; Nery OA; de Melo GNP; Corder RM; Rodrigues PT; Ferreira MU
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30782991
[TBL] [Abstract][Full Text] [Related]
17. Impact of Plasmodium vivax malaria and antimalarial treatment on cytochrome P450 activity in Brazilian patients.
Almeida AC; Elias ABR; Marques MP; de Melo GC; da Costa AG; Figueiredo EFG; Brasil LW; Rodrigues-Soares F; Monteiro WM; de Lacerda MVG; Lanchote VL; Suarez-Kurtz G
Br J Clin Pharmacol; 2021 Apr; 87(4):1859-1868. PubMed ID: 32997351
[TBL] [Abstract][Full Text] [Related]
18. Treatment of vivax malaria on the western border of Thailand.
Luxemburger C; van Vugt M; Jonathan S; McGready R; Looareesuwan S; White NJ; Nosten F
Trans R Soc Trop Med Hyg; 1999; 93(4):433-8. PubMed ID: 10674098
[TBL] [Abstract][Full Text] [Related]
19. Four Times of Relapse of Plasmodium vivax Malaria Despite Primaquine Treatment in a Patient with Impaired Cytochrome P450 2D6 Function.
Choi S; Choi H; Park SY; Kwak YG; Song JE; Shin SY; Baek JH; Shin HI; Oh HS; Kim YC; Yeom JS; Han JH; Kim MJ
Korean J Parasitol; 2022 Feb; 60(1):39-43. PubMed ID: 35247953
[TBL] [Abstract][Full Text] [Related]
20. Effects of CYP2D6 genotypes on Plasmodium vivax recurrence after primaquine treatment: A meta-analysis.
Park YA; Park KH; Yoon HY; Yee J; Gwak HS
Travel Med Infect Dis; 2022; 48():102333. PubMed ID: 35452835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
